|
|||
Clinical data | |||
---|---|---|---|
Routes of administration |
Oral (tablets) | ||
ATC code |
|
||
Legal status | |||
Legal status |
|
||
Pharmacokinetic data | |||
Bioavailability | 42% | ||
Biological half-life | 11,21 hours (in humans), 7 hours (in rats) |
||
Identifiers | |||
|
|||
Synonyms | Bromantan; Bromontan; Ladasten; ADK-709 |
||
CAS Number | |||
PubChem CID | |||
ChemSpider | |||
ECHA InfoCard | 100.213.907 | ||
Chemical and physical data | |||
Formula | C16H20BrN | ||
Molar mass | 306.246 g/mol | ||
3D model (Jmol) | |||
|
|||
|
|||
(what is this?) |
Bromantane (brand name Ladasten, also known in Russia as adamantylbromphenylamine) is an atypical psychostimulant and anxiolytic drug of the adamantane family that is used in Russia in the treatment of neurasthenia. Although the effects of the bromantane have been determined to be dependent on the dopaminergic and possibly serotonergic neurotransmitter systems, its exact mechanism of action is unknown, and it is distinct in its properties relative to typical psychostimulants such as amphetamine. Because of its unique aspects, bromantane has sometimes been described instead as an adaptogen and actoprotector.
In the 1960s, the adamantane derivative amantadine (1-aminoadamantane) was developed as an antiviral drug for the treatment of influenza. Other adamantane antivirals subsequently followed, such as rimantadine (1-(1-aminoethyl)adamantane) and adapromine (1-(1-aminopropyl)adamantane). It was serendipitously discovered in 1969 that amantadine possesses central dopaminergic psychostimulant-like properties, and subsequent investigation revealed that rimantadine and adapromine also possess such properties. Amantadine was then developed and introduced for the treatment of Parkinson's disease due to its ability to increase dopamine levels in the brain. It has also notably since been used to help alleviate fatigue in multiple sclerosis.